Browse studies

Find your next paid study

54 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+6 more

Estimated

~$10 – $7,500

AstraZenecaNCT07115043

Phase 2

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients …

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)

Phase 1

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tum…

Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more

Estimated

~$10 – $8,750

Observational

The Vanguard Study: Testing a New Way to Screen for Cancer

The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized control…

Bladder CarcinomaBreast CarcinomaColorectal Carcinoma+8 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06995898

Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumo…

Breast CarcinomaFallopian Tube CarcinomaOvarian Carcinoma+5 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT03604315

Phase 1

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer th…

Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05950464

Phase 2

MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopi…

Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian Carcinoma+15 more

Estimated

~$10 – $6,250

Phase 2

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolli…

Advanced Solid TumorMelanomaHead and Neck Cancer+11 more

Estimated

~$10 – $7,500

Daiichi SankyoNCT06172478

Phase 2

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the tr…

Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma

Estimated

~$10 – $6,250

Emory UniversityNCT05998135

Phase 2

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisf…

AmyloidosisBasal Cell CarcinomaBiliary Tract Carcinoma+26 more

Estimated

~$10 – $6,250

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the …

Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more

Estimated

~$10 – $8,750

Accent TherapeuticsNCT06799065

An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform aph…

Solid Tumor, AdultColorectal CancerNon Small Cell Lung Cancer+14 more

Estimated

~$10 – $1,050

A2 Biotherapeutics Inc.NCT04981119